SP
REGN icon

Symmetry Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Symmetry Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-288
Closed -$223K – 306
2026
Q1 		$223K Buy
288
+7
+2% +$5.36K 0.01% 183
2025
Q4 		$217K Buy
+281
New +$191K 0.01% 185
2024
Q3 		– Sell
-779
Closed -$819K – 415
2024
Q2 		$819K Hold
779
– – 0.04% 200
2024
Q1 		$750K Sell
779
-94
-11% -$89.4K 0.06% 225
2023
Q4 		$770K Sell
873
-310
-26% -$255K 0.04% 207
2023
Q3 		$974K Sell
1,183
-163
-12% -$128K 0.05% 185
2023
Q2 		$967K Sell
1,346
-403
-23% -$311K 0.05% 195
2023
Q1 		$1.44M Buy
1,749
+164
+10% +$124K 0.08% 136
2022
Q4 		$1.14M Sell
1,585
-79
-5% -$58.3K 0.07% 161
2022
Q3 		$1.15M Buy
1,664
+134
+9% +$84.3K 0.08% 148
2022
Q2 		$904K Sell
1,530
-1,002
-40% -$651K 0.06% 189
2022
Q1 		$1.77M Buy
2,532
+1,637
+183% +$1.04M 0.11% 103
2021
Q4 		$565K Hold
895
– – 0.04% 354
2021
Q3 		$493K Buy
895
+80
+10% +$49.7K 0.03% 411
2021
Q2 		$455K Buy
815
+222
+37% +$112K 0.03% 461
2021
Q1 		$281K Sell
593
-539
-48% -$262K 0.02% 572
2020
Q4 		$547K Sell
1,132
-912
-45% -$492K 0.04% 347
2020
Q3 		$1.14M Buy
2,044
+898
+78% +$544K 0.1% 137
2020
Q2 		$715K Buy
+1,146
New +$650K 0.09% 95

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Symmetry Partners's REGN Position: Q2 2026 in Review

Symmetry Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 288 shares — an estimated $223K sold.

Symmetry Partners first reported a position in REGN in Q2 2020 and held it in 19 quarters. The position peaked at $1.77M in Q1 2022. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Symmetry Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Symmetry Partners sold 288 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $223K.
  • Symmetry Partners first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 19 quarters.
  • Symmetry Partners's Regeneron Pharmaceuticals position peaked at $1.77M in Q1 2022.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Symmetry Partners's 13F filing for Q2 2026, filed 23 Jul 2026.